CME Video Highlights: Advancing Knowledge and Tackling Important Clinical Questions in Atrial Fibrillation Management

Presented By:		CME Video Highlights, 2009 Video Highlights from VBWG Town Hall

Program Description:	This CME activity consists of an educational component (ie, slides, audio lecture, newsletter) in an electronic format, followed by an online post-test. Estimated time to complete this activity, including review of materials, is 1 hour.
General Information:	Requirements for Successful Completion: This CME activity consists of an educational component (ie, slides, audio lecture, newsletter) in an electronic format, which is followed by an online post-test. There is no fee to participate in this CME activity or to receive CME credit. Certificates are awarded upon successful completion (80% proficiency) of the post-test. In order to receive credit, participants must view the presentaion in its entirety. Media: Internet Release Date:    December 18, 2009 Expiration Date:  December 17, 2011
Target Audience:	Clinical cardiologists, electrophysiologists, and other healthcare professionals who treat patients with cardiac arrhythmias.
Program Overview:	Atrial fibrillation (AF) is a complex, multifactorial arrhythmia. The most common arrhythmia in adults, AF is associated with an increase in the risk of stroke and heart failure and is a substantial cause of morbidity and mortality. With the prevalence of this arrhythmia steadily increasing, treatment represents a major challenge to cardiologists and internists. At a recent VBWG town hall meeting held in conjunction with the American Heart Association Scientific Sessions 2009, a prestigious international faculty provided state-of-the-art information about AF. Pharmacologic and ablation strategies for restoring and maintaining sinus rhythm and new approaches to stroke prevention were discussed in the context of guidelines and new clinical data. This video highlight summarizes the key points made during these presentations.
Learning Objectives:	• Identify patients with AF and associated comorbidities to better understand treatment implications • Cite data supporting first-line therapy with newer, efficacious, and safer antiarrhythmic drugs • Modify clinical practice behaviors based on insights gleaned from recent clinical trials • Review the risk factors associated with AF
Faculty Disclosure:	The University of Florida College of Medicine has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they simply are noted here to fully inform participants. Carl J. Pepine, MD, has indicated that he has financial arrangements or affiliations with Abbott Laboratories, Angioblast Systems, AstraZeneca, AtCor medical, Baxter Healthcare, Berlex Labortories/Bayer Healthcare, Boehringer Ingelheim, Cardium Therapeutics, CVS-K-10, Daiichi Sankyo, Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, MEDCON LLC, NicOX, NIH/NHLBI, Novartis/Cleveland Clinic, Pfizer Inc., sanofi-aventis, Schering-Plough Corporation, SLACK Inc., Takeda Pharmaecuticals North America Inc., Viron Therapeutics, Inc. Peter R. Kowey, MD, has indicated that he has financial arrangements or affiliations with Astellas Pharma Inc., AstraZeneca, CariodNet, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., sanofi-aventix, Wyeth. Stefan H. Hohnloser, MD, has indicated that he has financial arrangements or affiliations with ARYx Therapeutics, Boehringer Ingelheim, Cardiome Pharma Corporation, sanofi-aventis, St. Jude Medical, Inc. Francis E. Marchlinski, MD, has indicated that he has financial arrangements or affiliations with Biosense Webster, Inc., Boston Scientific Corporation, CardioInsight Technologies Inc., GE Healthcare, Medtronic, Inc., sanofi-aventis, St. Jude Medical, Inc. Deepak L. Bhatt, MD, has indicated that he has financial arrangements or affiliations with AstraZeneca, Bristol-Myers Squibb, Eisai Inc., Ethicon, Inc., Heartscape Technologies, Inc., sanofi-aventis, The Medicines Company.
Continuing Medical Education Credit:
	Accreditation
	The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
	Credit
	The University of Florida College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
	This continuing education activity was planned in accordance with the ACCME essentials and reviewed by Carl J. Pepine, MD, Program Chair.
	Click here for disclosure and disclaimer information
Commercial Support:	This CME activity is supported by an educational grant from sanofi-aventis U.S.
System Requirements:	In order to view the presentation, your computer must have a media player such as Windows Media Player, Quicktime, or RealOne.
CME Contact:	For any question regarding this Internet CME activity, please contact the Office of Continuing Medical Education at 352-265-8081.
	The University of Florida College of Medicine has received permission to use this copyrighted material within a CME activity on the internet.

Take this presentation with you:
Download this Online Lecture as an MP3 and load it onto your iPod or other portable audio player.
MP3 Audio File
(Right-click and select "Save Target As..." to download)